Summary
Signal counts
Assets tracked: 3
Watchlist assets: 1
Registry stop assets: 0
Sponsor overview
Massachusetts General Hospital
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT02314364 | https://clinicaltrials.gov/study/NCT04824937 | https://clinicaltrials.gov/study/NCT01846871
Assets
Linked programs
- SBRT with protons or photons: Low Signal (0/5)
- Telaglenastat: Timeline Staleness Signal (4/5)
- Tivozanib: Low Signal (1/5)